Months after recovery from mild Covid-19 – when antibody levels in the blood have declined – immune cells in bone marrow remain ready to pump out new antibodies against the coronavirus, researchers reported on May 24 in Nature. And according to a new U.S. study, young children appear to be significant carriers of more contagious variants of the new coronavirus, such as the ones identified in the UK and in California.
Topline results from two of Merck’s Phase III pediatric trials show the company’s investigational 15-valent pneumococcal conjugate vaccine, V114, may be safe and effective in healthy children.
Jerusalem-based SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. Participating in the round were OrbiMed, Israel Biotech Fund, Integra Holdings and the Cystic Fibrosis Foundation.
Passage Bio Inc. and InformedDNA announced a collaboration to provide no-cost genetic counseling and testing for adults who have been diagnosed by their physicians with Frontotemporal Dementia (FTD).
The microscopic organisms living in our intestines may influence the severity of Covid-19 and the body’s immune response to it, and could account for lingering symptoms, researchers reported.
rBIO launched with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.
Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.
Biogen reported the company’s Q3 2020 financial results and stated that R&D would be halted on the experimental multiple sclerosis drug opicinumab.
Shares of Solid Biosciences skyrocketed in trading after the company announced the U.S. Food and Drug Administration lifted the clinical hold on the IGNITE DMD Phase I/II clinical trial.
According to a study published in Nature Communications, enzymes that are used by bacteria to break down mucus in the gut can potentially be useful biomarkers for intestinal diseases.
